These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20504240)

  • 21. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.
    Rotger M; Taffe P; Bleiber G; Gunthard HF; Furrer H; Vernazza P; Drechsler H; Bernasconi E; Rickenbach M; Telenti A;
    J Infect Dis; 2005 Oct; 192(8):1381-6. PubMed ID: 16170755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Tsuchiya K; Tanaka N; Joya A; Hamada Y; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    J Antimicrob Chemother; 2014 Dec; 69(12):3320-8. PubMed ID: 25151207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variations in the UDP-glucuronosyltransferase 1A1 gene for the development of unconjugated hyperbilirubinemia in Taiwanese.
    Huang YY; Huang MJ; Yang SS; Teng HC; Huang CS
    Pharmacogenomics; 2008 Sep; 9(9):1229-35. PubMed ID: 18781851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
    Rodríguez-Nóvoa S; Morello J; González M; Vispo E; Barreiro P; González-Pardo G; Jiménez-Nácher I; Gonzalez-Lahoz J; Soriano V
    AIDS; 2008 Nov; 22(18):2535-7. PubMed ID: 19005277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
    Lozano R; Domeque N; Apesteguia AF
    J Clin Pharmacol; 2014 Feb; 54(2):161-7. PubMed ID: 24243081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood.
    Grant DJ; Hall IJ; Eastmond DA; Jones IM; Bell DA
    Mutat Res; 2004 May; 560(1):1-10. PubMed ID: 15099818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
    Meza-Junco J; Chu QS; Christensen O; Rajagopalan P; Das S; Stefanyschyn R; Sawyer MB
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):1-4. PubMed ID: 19672597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia.
    Carpenter SL; Lieff S; Howard TA; Eggleston B; Ware RE
    Am J Hematol; 2008 Oct; 83(10):800-3. PubMed ID: 18756540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between UGT 1A1 Gly71Arg (G71R) polymorphism and neonatal hyperbilirubinemia.
    Prachukthum S; Gamnarai P; Kangsadalampai S
    J Med Assoc Thai; 2012 Jan; 95 Suppl 1():S13-7. PubMed ID: 23964438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mutation analysis of UGT1A1 gene in patients with unconjugated hyperbilirubinemia].
    Sun SC; Zhou ZM; Chen QR; Peng YS; Tu CQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Aug; 30(4):425-8. PubMed ID: 23926009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
    Ribaudo HJ; Daar ES; Tierney C; Morse GD; Mollan K; Sax PE; Fischl MA; Collier AC; Haas DW;
    J Infect Dis; 2013 Feb; 207(3):420-5. PubMed ID: 23148286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype frequencies of UDP-glucuronosyltransferase 1A1 promoter gene polymorphism in the population of healthy Croatian pre-scholars.
    Marinković N; Pasalić D; Grsković B; Ferencak G; Honović L; Rukavina AS
    Coll Antropol; 2008 Sep; 32(3):725-9. PubMed ID: 18982743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A causal relationship between UDP-glucuronosyltransferase 1A1 promoter polymorphism and idiopathic hyperbilirubinemia in Turkish newborns.
    Ergin H; Bican M; Atalay OE
    Turk J Pediatr; 2010; 52(1):28-34. PubMed ID: 20402064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.
    Avihingsanon A; Tongkobpetch S; Kerr SJ; Punyawudho B; Suphapeetiporn K; Gorowara M; Ruxrungtham K; Shotelersuk V
    J Acquir Immune Defic Syndr; 2015 May; 69(1):e36-7. PubMed ID: 25622064
    [No Abstract]   [Full Text] [Related]  

  • 37. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab.
    Lee JS; Wang J; Martin M; Germer S; Kenwright A; Benayed R; Spleiss O; Platt A; Pilson R; Hemmings A; Weinblatt ME; Kaplowitz N; Krasnow J
    Pharmacogenet Genomics; 2011 Jul; 21(7):365-74. PubMed ID: 21412181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic factors related to unconjugated hyperbilirubinemia amongst adults.
    Huang CS; Huang MJ; Lin MS; Yang SS; Teng HC; Tang KS
    Pharmacogenet Genomics; 2005 Jan; 15(1):43-50. PubMed ID: 15864125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bilirubin and UGT1A1*28 are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting.
    Ekblom K; Marklund SL; Johansson L; Osterman P; Hallmans G; Weinehall L; Wiklund PG; Hultdin J
    Cerebrovasc Dis; 2010; 30(6):590-6. PubMed ID: 20948202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.